GC Biopharma announced on the 30th that its operating profit for the first quarter of this year was 8 billion won, reflecting a turnaround from a loss during the same period last year.
Sales for the same period increased by 7.6% to 383.8 billion won, and net income for the period turned positive at 22.3 billion won.
GC Biopharma explained that the turnaround in profitability was influenced by improvements in the revenue structure of domestic blood products and an increase in global sales of high-revenue products, including "Aliglo."
The company aims for annual sales of $100 million (1.4 billion won) for its blood product Aliglo. GC Biopharma analyzed that the impact of tariffs on sales of the product in the United States will also be limited.
A GC Biopharma official noted, "Total sales this year are expected to be between 1.8 trillion won and 1.9 trillion won, and research and development (R&D) expenses will remain at about 9.5% to 10% of sales," adding, "We are continuing growth overseas through the expansion of licensing countries for the chickenpox and flu vaccines and orders, and we are experiencing structural growth due to the expansion of the new market for the treatment of Hunter syndrome, 'Huntera.'"